Pharmaceutical application of agaricin-4-o-β-d-glucoside and its pharmaceutical composition

A technology of larchoresin and glucoside, which is applied in the field of medicine, can solve the problem that there is no relevant literature report on larchoresin-4-O-β-D-glucoside, and achieve the effect of less toxic and side effects

Active Publication Date: 2019-01-25
THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT) +2
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there is no relevant literature report on the application of agaricin-4-O-β-D-glucoside in the treatment of influenza.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical application of agaricin-4-o-β-d-glucoside and its pharmaceutical composition
  • Pharmaceutical application of agaricin-4-o-β-d-glucoside and its pharmaceutical composition
  • Pharmaceutical application of agaricin-4-o-β-d-glucoside and its pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027]Example 1 Separation, purification and structural identification of larchoresin-4-O-β-D-glucoside

[0028] According to the existing extraction and separation methods in this field, extract and separate from the Radix Radix Radix Radix methanol extract to obtain larchoresin-4-O-β-D-glucoside, specifically, suspend 500g of Radix Radix Radix Radix methanol extract with water, and then use ethyl acetate, Extraction with n-butanol, 70 g of n-butanol is further desugared by macroporous resin HPD100, and 95% ethanol is collected to recover the solvent to obtain about 45 g of extract. The extract was subjected to silica gel column chromatography (200-300 mesh, 5×30cm), eluted with chloroform-methanol gradient (100:0-98:2-95:5-9:1-2:1-0:1, v / v) 13 components Fr.1-Fr.13 are obtained. Fr.11 was purified by preparative MPLC and eluted with methanol-water gradient (0:100-100:0, v / v) to obtain 7 components A-G. Fr.C was further purified by silica gel column chromatography to obtain ...

Embodiment 2

[0031] Example 2 Preparation of larchoresin-4-O-β-D-glucoside tablet

[0032] Weigh each component according to the following formula:

[0033]

[0034] Tablets were prepared according to the conventional preparation method of tablets in the field of pharmacy, and 1000 tablets were made in total, each containing 5 mg of agaricin-4-O-β-D-glucoside. The usage of this tablet is: 2-4 tablets each time, 3 times a day, seven days as a course of treatment.

Embodiment 3

[0035] Example 3 Preparation of larchoresin-4-O-β-D-glucoside capsules

[0036] Weigh each component according to the following formula:

[0037]

[0038] Prepared according to the conventional method of capsules in the field of pharmacy, a total of 1000 capsules were made, and each capsule contained 5 mg of agaricin-4-O-β-D-glucoside. Usage of the capsule: 2-4 capsules each time, 3 times a day, seven days as a course of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of lariciresinol-4-O-beta-D-glucoside in the preparation of drugs for treating or preventing flu and related inflammatory diseases caused by influenza virus. The application of lariciresinol-4-O-beta-D-glucoside in clinical treatment of influenza virus diseases has characteristics of safety, effectivity and little toxic or side effect. The invention also provides a pharmaceutical composition, an active ingredient of which comprises lariciresinol-4-O-beta-D-glucoside. By cytopathic-effect inhibition assay, it is verified that lariciresinol-4-O-beta-D-glucoside has an effect of inhibiting replication of influenza virus in the treatment mode. The result proves that lariciresinol-4-O-beta-D-glucoside has obvious effect of inhibiting influenza virus in the treatment mode. Selection index SI is greater than 4. The lariciresinol-4-O-beta-D-glucoside has advantages of low toxicity and high effectiveness.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to the application of larchoresin-4-O-β-D-glucoside in treating or preventing influenza and inflammatory diseases caused by influenza virus. The invention also relates to a pharmaceutical composition containing the composition for resisting influenza virus and treating inflammatory diseases caused by influenza virus. Background technique [0002] Influenza (abbreviated as flu) is an acute respiratory infection caused by influenza virus, which can be transmitted through the air. Although seasonal influenza is self-limiting, because influenza virus can cause secondary bacterial infection, the infected person will develop pneumonia and severe lung damage, resulting in high morbidity and mortality. According to statistics, the annual influenza season Between 250,000 and 500,000 people died of influenza worldwide. Existing anti-influenza drugs M2 ion channel inhibitors (amantadine drugs...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7048A61P31/16A61P29/00
Inventor 杨子峰姜志宏李菁周倍贤王玉涛李征途陈荣昌钟南山
Owner THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap